Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Kite Pharma Shows Positive results from non-Hodgkin lymphoma study

Authored by James Sheppard

The California based biotech company Kite Pharma announced that it has achieved positive clinical data from its non-Hodgkin’s lymphoma treatment, KTE-C19, the company’s leading drug candidate.

KTE-C19 is being developed for use in patients with diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of therapy. DLBCL is the most common form of non-Hodgkin’s lymphoma and results in around 10,000 deaths per year in the United States.

The data came from 8 patients enrolled in the 15 person trial. Of the 15 patients, 13 had enough information collected to measure the response to the treatment. The results were from the second treatment group of the Phase I/IIa clinical study which was being conducted by the National Cancer Institute and published in the American Society of Clinical Oncology’s Journal of Clinical Oncology.

The data comes on the back of the company’s highly successful IPO in June 2014. The results sent Kite’s share price soaring by 29%. The company is now planning to file an investigational new drug application in Q4 2014 for a new clinical study using KTE-C19.

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , | Leave a comment

Contact Us

   Head Office
Liftstream Ltd.
111 Buckingham Palace Road,
   Tel: ​+44 (0)20 4515 1123

Register your CV

Apply for sector specific vacancies or request a confidential discussion

Registered in England No: 5009233
VAT: 843679292

Follow Us